Review
Oncology
Hailing Liu, Xiao Shi, Huizi Fang, Lei Cao, Yi Miao, Xiaoli Zhao, Wei Wu, Wei Xu, Jianyong Li, Lei Fan
Summary: This study systematically reviewed the use of autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma (MCL) and found that the benefit of ASCT has been weakened in the era of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HiDAC) treatment. Alternative first-line maintenance strategies should be explored.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Malte Roerden, Stefan Wirths, Martin Soekler, Wolfgang A. Bethge, Wichard Vogel, Juliane S. Walz
Summary: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) is a standard frontline treatment for fit mantle cell lymphoma (MCL) patients. However, lymphoma cell contamination of stem cell grafts may lead to poor outcomes. Analyzing residual MCL cells in autologous grafts can improve risk assessment for MCL patients undergoing Auto-HSCT.
Article
Health Care Sciences & Services
Paul Gressenberger, Philipp Jud, Gabor Kovacs, Sonja Kreuzer, Hans-Peter Brezinsek, Katharina Guetl, Viktoria Muster, Ewald Kolesnik, Albrecht Schmidt, Balazs Odler, Gabriel Adelsmayr, Peter Neumeister, Luka Brcic, Sabine Zenz, Kurt Weber, Thomas Gary, Marianne Brodmann, Winfried B. Graninger, Florentine C. Moazedi-Fuerst
Summary: Systemic sclerosis (SSc) is a difficult-to-treat autoimmune disease characterized by vascular damage and organ fibrosis. Autologous hematopoietic stem cell transplantation (AHSCT) may be considered for high-risk SSc patients, but the need for additional immunosuppressive therapies such as rituximab (RTX) post-AHSCT remains unclear. This report highlights the potential efficacy of RTX in SSc patients who do not respond well to AHSCT, with improved clinical symptoms and organ functions observed after RTX treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Immunology
Michael Gernert, Hans-Peter Tony, Matthias Froehlich, Eva Christina Schwaneck, Marc Schmalzing
Summary: This study investigated the use of immunosuppressive medication (IS) after autologous hematopoietic stem cell transplantation (aHSCT) in systemic sclerosis (SSc) patients. The results showed that approximately 60% of SSc patients required IS after aHSCT for disease control. Rituximab was found to be an effective treatment option. Long-term data suggested that aHSCT is safe.
FRONTIERS IN IMMUNOLOGY
(2022)
Letter
Oncology
Anina Mathys, Ulrike Bacher, Yara Banz, Myriam Legros, Behrouz Mansouri Taleghani, Urban Novak, Thomas Pabst
Summary: Intensive induction therapy and high dose chemotherapy followed by autologous stem cell transplantation for mantle cell lymphoma patients show high relapse and mortality rates. Relapsed patients have shorter survival, with those receiving BTK inhibitors showing slightly longer survival. New treatment options, including CAR T-cell therapy, are needed even after HDCT/ASCT.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Oncology
Kai Kroeger, Jan Siats, Andrea Kerkhoff, Georg Lenz, Matthias Stelljes, Hans Theodor Eich, Gabriele Reinartz
Summary: This study analyzed the long-term outcome of 22 patients with mantle cell lymphoma who underwent total body irradiation (TBI)-based conditioning prior to stem cell transplantation (SCT). The results support the effectiveness of TBI-based high-dose therapy followed by SCT in this unfavorable disease. The use of recently approved agents and traditional SCT opens up possibilities for personalized treatment for MCL.
Article
Hematology
Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio Chavez, Yago Nieto, Justin M. Darrah, Uttam Rao, Michael T. Byrne, David A. Bond, Kami J. Maddocks, Michael A. Spinner, Ranjana H. Advani, Hatcher J. Ballard, Jakub Svoboda, Anurag K. Singh, Joseph P. McGuirk, Dipenkumar Modi, Radhakrishnan Ramchandren, Jason Romancik, Jonathon B. Cohen, Matthew J. Frigault, Yi-Bin Chen, Anthony Serritella, Justine Kline, Stephen Ansell, Sunita Nathan, Maryam Rahimian, Robin M. Joyce, Mansi Shah, Kevin A. David, Steven Park, Anne W. Beaven, Alma Habib, Veronika Bachanova, Shazia Nakhoda, Nadia Khan, Ryan C. Lynch, Stephen D. Smith, Vincent T. Ho, Ann LaCasce, Philippe Armand, Alex F. Herrera
Summary: Autologous stem cell transplantation (ASCT) following anti-PD-1 therapy shows promising outcomes for relapsed/refractory Hodgkin lymphoma (HL) patients, even in high-risk cases, with favorable survival rates observed.
Letter
Medicine, General & Internal
Leonid L. Yavorkovsky
Summary: The median survival of mantle-cell lymphoma is a puzzling issue. Despite the historically modest benefits of rituximab therapy, the introduction of rituximab has substantially improved the survival probability among patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Miriam Marangon, Carlo Visco, Anna Maria Barbui, Annalisa Chiappella, Alberto Fabbri, Simone Ferrero, Sara Galimberti, Stefano Luminari, Gerardo Musuraca, Alessandro Re, Vittorio Ruggero Zilioli, Marco Ladetto
Summary: Mantle Cell Lymphoma (MCL) is a rare lymphoproliferative disorder that has been regarded as incurable since its identification. For two decades, allogeneic transplantation has been the only option capable of ensuring prolonged remissions and potential cure. However, its application has been limited by feasibility constraints and significant toxicity, particularly in elderly patients.
Article
Oncology
Yazeed Sawalha, Tomas Radivoyevitch, Xuefei Jia, Katherine Tullio, Robert M. Dean, Brad Pohlman, Brian T. Hill, Matt Kalaycio, Navneet S. Majhail, Deepa Jagadeesh
Summary: Younger patients with private insurance and receiving treatment at academic facilities are more likely to undergo autologous stem cell transplantation for mantle cell lymphoma, which is associated with improved survival rates.
LEUKEMIA & LYMPHOMA
(2022)
Article
Hematology
Bernd Metzner, Thomas H. Mueller, Jochen Casper, Christoph Kimmich, Claus-Henning Koehne, Eduard Petershofen, Andrea Renzelmann, Ruth Thole, Andreas Voss, Martin Dreyling, Eva Hoster, Wolfram Klapper, Christiane Pott
Summary: Long-term clinical and molecular remissions following ASCT are achievable in patients with MCL. Ten-year overall survival rates were 64% and 50% after first-line and second-line ASCT, respectively, while progression-free survival rates were 52% and 20%. Treatment-related mortality after ASCT was low at 1.5%.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Review
Oncology
Yazeed Samara, Matthew Mei
Summary: Standard second-line therapy for relapsed and/or refractory Hodgkin lymphoma patients includes salvage therapy and autologous stem cell transplantation. However, the introduction of novel agents and treatment strategies has changed patients' decision-making and pre-transplant treatment, as well as post-transplant maintenance therapy.
Article
Hematology
Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muff Ly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen -Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai
Summary: The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has significantly changed over the past decade with the use of brentuximab vedotin (BV) and PD-1 inhibitors. A study comparing outcomes from 2011 to 2020 with those from 2001 to 2010 showed improved overall survival (OS) and increased postprogression survival in the modern era, attributed to the use of BV and PD-1 inhibitors. Factors associated with inferior progression-free survival (PFS) included age ≥45 years, primary refractory disease, and lack of complete remission pre-AHCT, while receipt of a PD-1 inhibitor-based regimen pre-AHCT was associated with superior PFS.
Article
Hematology
Robert Puckrin, Neil Chua, Kelly Chin, Anthea Peters, Peter Duggan, Mona Shafey, Jan Storek, Kareem Jamani, Carolyn Owen, Douglas Stewart
Summary: ASCT demonstrates high rates of durable remission in relapsed FL, with long-term follow-up revealing that more than 50% of transplanted patients may be functionally cured of their lymphoma. The optimal timing to consider ASCT is at first or second relapse, regardless of POD24 status.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Multidisciplinary Sciences
Saaya Tsutsue, Shinichi Makita, Jingbo Yi, Bruce Crawford
Summary: This study focuses on the economic burden and survival of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Japan. It found that hospital stay and potential heart disease complications due to line of treatment were the primary drivers of total medical cost for patients receiving second or third line therapy for rrDLBCL.
Review
Hematology
Lorenzo Falchi, Santosha A. Vardhana, Gilles A. Salles
Summary: Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have undergone significant changes in the past two decades due to the introduction of highly active immunotherapies. Bispecific antibodies (BsAb) have emerged as a promising immunotherapeutic for B-NHL, with anti-CD20xCD3 BsAb showing remarkable single-agent activity. However, further research is needed to determine the optimal deployment of these drugs, ideal combination partners, strategies for minimizing toxicity, and pharmacodynamic biomarkers of response and resistance.
Review
Hematology
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles
Summary: Relapsed Mantle cell lymphoma (MCL) has a poor prognosis and there is no standard treatment. This study examined the outcomes of salvage therapy in MCL patients who failed Bruton tyrosine kinase inhibitor (BTKi) therapy, showing shorter overall survival in this group compared to those who received post-BTKi therapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Hematology
David Qualls, Brandon S. Imber, Michelle Okwali, Paul A. Hamlin, Anita Kumar, Oscar B. Lahoud, Matthew J. Matasar, Ariela Noy, Colette Owens, Andrew D. Zelenetz, Victoria S. North, Heiko Schoeder, Ahmet Dogan, Gilles Salles, Joachim Yahalom, Lorenzo Falchi
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Hematology
Caroline Algrin, Louis Perol, Elise Chapiro, Lucile Baseggio, Karim Maloum, Catherine Settegrana, Jean-Francois Lesesve, Justine Siavellis, Alain Delmer, Anne-Sophie Michallet, Emmanuelle Ferrant, Pierre Feugier, Cecile Tomowiak, Annie Brion, David Ghez, Luc-Matthieu Fornecker, Sarah Ivanoff, Stephanie Struski, Laurent Sutton, Isabelle Radford-Weiss, Virginie Eclache, Christine Lefebvre, Veronique Leblond, Florence Nguyen-Khac, Damien Roos-Weil, Innovative Leukemia Org
Article
Oncology
Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Catherine Thieblemont, Michal Szymczyk, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hubel, Corinne Haioun, Rene Olivier Casasnovas, Christian Schmidt, Kamal Bouabdallah, Vincent Ribrag, Lothar Kanz, Jan Durig, Bernd Metzner, David Sibon, Morgane Cheminant, Barbara Burroni, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Martin Dreyling
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies for which the primary end point has already been reported. This study confirms the previously observed substantially prolonged time to treatment failure and shows an improvement in overall survival for patients with Mantle Cell Lymphoma. Some patients with MCL may be cured.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Julien Broseus, Sebastien Hergalant, Julia Vogt, Eugen Tausch, Markus Kreuz, Anja Mottok, Christof Schneider, Caroline Dartigeas, Damien Roos-Weil, Anne Quinquenel, Charline Moulin, German Ott, Odile Blanchet, Cecile Tomowiak, Gregory H. Lazarian, Pierre Rouyer, Emil Chteinberg, Stephan Bernhart, Olivier Tournilhac, Guillaume Gauchotte, Sandra Lomazzi, Elise Chapiro, Florence Nguyen-Khac, Celine Chery, Frederic Davi, Mathilde Hunault, Remi Houlgatte, Andreas Rosenwald, Alain Delmer, David Meyre, Marie-Christine Bene, Catherine Thieblemont, Peter Lichter, Ole Ammerpohl, Jean-Louis Gueant, Romain Guieze, Jose Ignacio Martin-Subero, Florence Cymbalista, Pierre Feugier, Reiner Siebert, Stephan Stilgenbauer
Summary: This study characterizes the DNA methylation and transcriptomic profiles of Richter syndrome (RS), and develops classifiers for RS-type de novo diffuse large B-cell lymphomas (DLBCLs).
NATURE COMMUNICATIONS
(2023)
Article
Hematology
Reid W. Merryman, Laure Michaud, Robert Redd, Patrizia Mondello, Hyesun Park, Gabriela Spilberg, Matthew Robertson, Eleanor Taranto, Gulrayz Ahmed, Matthew Chase, Erin Jeter, Inhye E. Ahn, Jennifer R. Brown, Jennifer Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Gilles Salles, Andrew D. Zelenetz, Philippe Armand, Heiko Schoeder, Heather Jacene
Summary: This study found that interim PET scans after 2-4 cycles of frontline chemoimmunotherapy can predict progression-free survival in follicular lymphoma patients, and may be used as a tool for response-adapted treatment strategies.
Article
Hematology
Asma Beldi-Ferchiou, Jean-Philippe Jais, Herve Ghesquieres, Rene Olivier Casasnovas, Herve Tilly, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Aurore Perrot, Emmanuelle Nicolas-Virelizier, Gilles Salles, Nathalie Godard, Imen Zamali, Jean-Marc Schiano De Colella, Alexis Claudel, Bernadette Corront, Lucie Oberic, Josette Briere, Philippe Gaulard, Catherine Thieblemont, Marie-Helene Delfau-Larue
Summary: Low baseline NK-cell counts (NKCCs) in DLBCL patients are associated with poor prognosis. Lenalidomide maintenance does not affect the prognostic value of low NKCCs in DLBCL patients. Improving NK-cell function could be a potential therapeutic strategy to improve outcomes in DLBCL.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Sammara Chaubard, Amira Marouf, David Lavergne, Francois Lemonnier, Julien Rossignol, Aline Clavert, Remy Gressin, Guillaume Cartron, Agathe Waultier-Rascalou, Jacques Vargaftig, Gilles Salles, Emmanuel Bachy, Herve Ghesquieres, Olivier Tournilhac, Adrien Chauchet, Steven Le Gouill, Gandhi Damaj, Luc-Matthieu Fornecker, David Sibon, Lucie Oberic, Jean-Marie Michot, Philippe Gaulard, Olivier Hermine, Lucile Couronne, Arnaud Jaccard
Summary: We conducted a retrospective multi-center study to evaluate the efficacy of the MGAD regimen combined with 'sandwich' radiotherapy in patients with localized extranodal NK/T-cell lymphoma. The results showed high rates of complete remission and favorable progression-free and overall survival at 2 and 5 years. However, a significant proportion of patients experienced relapse and there were manageable side effects. Monitoring of asparaginase activity revealed drug inactivation in a considerable number of patients. Short-term MGAD chemoradiotherapy appears to be a viable treatment option for newly diagnosed patients with localized extranodal NK/T-cell lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Dipti Talaulikar, Cecile Tomowiak, Elise Toussaint, Pierre Morel, Prashant Kapoor, Jorge J. Castillo, Alain Delmer, Eric Durot
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2023)
Article
Hematology
Anne-Sophie Michallet, Remi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valerie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Lysiane Molina, Veronique Leblond, Cecile Tomowiak, Sophie de Guibert, Frederique Orsini-Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan-Graczyk, Jean-Pierre Vilque, Therese Aurran Schleinitz, Florence Cymbalista, Stephane Lepretre, Vincent Levy, Florence Nguyen-Khac
Summary: In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), a fixed-duration immunochemotherapy approach yielded deep and sustained peripheral blood measurable residual disease (MRD) responses, high survival rates, and low long-term toxicity. A randomized trial is needed to compare this approach with a chemotherapy-free strategy. The ICLL-07 trial demonstrated promising results with 4-year progression-free and overall survival rates of 95.5% and 96.2%, respectively.
Article
Oncology
Laurence Brugieres, Nathalie Cozic, Roch Houot, Charlotte Rigaud, David Sibon, Julia Arfi-Rouche, Pierre Bories, Anne S. Cottereau, Alain Delmer, Stephane Ducassou, Nathalie Garnier, Laurence Lamant, Amaury Leruste, Frederic Millot, S. Moalla, Franck Morschhauser, Marie Nolla, Anne Pagnier, Yves Reguerre, Loic Renaud, Anne Schmitt, Mathieu Simonin, Arnaud Verschuur, Nathalie Hoog Labouret, Celine Mahier Ait Oukhatar, Gilles Vassal
Summary: The study examined the safety and efficacy of crizotinib in ALK-positive anaplastic large-cell lymphoma (ALK+ ALCL) patients, showing that crizotinib is effective in relapsed/refractory patients, but a large proportion experience relapse after discontinuation. Rating: 8/10.
EUROPEAN JOURNAL OF CANCER
(2023)
Correction
Oncology
Sonja I. Berndt, Joseph Vijai, Yolanda Benavente, Nicola J. Camp, Alexandra Nieters, Zhaoming Wang, Karin E. Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, Christine F. Skibola, Lindsay M. Morton, Angela R. Brooks-Wilson, Lauren R. Teras, Charles Breeze, Joshua Arias, Hans-Olov Adami, Demetrius Albanes, Kenneth C. Anderson, Stephen M. Ansell, Bryan Bassig, Nikolaus Becker, Parveen Bhatti, Brenda M. Birmann, Paolo Boffetta, Paige M. Bracci, Paul Brennan, Elizabeth E. Brown, Laurie Burdett, Lisa A. Cannon-Albright, Ellen T. Chang, Brian C. H. Chiu, Charles C. Chung, Jacqueline Clavel, Pierluigi Cocco, Graham Colditz, Lucia Conde, David V. Conti, David G. Cox, Karen Curtin, Delphine Casabonne, Immaculata De Vivo, Arjan Diepstra, W. Ryan Diver, Ahmet Dogan, Christopher K. Edlund, Lenka Foretova, Joseph F. Fraumeni, Attilio Gabbas, Herve Ghesquieres, Graham G. Giles, Sally Glaser, Martha Glenn, Bengt Glimelius, Jian Gu, Thomas M. Habermann, Christopher A. Haiman, Corinne Haioun, Jonathan N. Hofmann, Theodore R. Holford, Elizabeth A. Holly, Amy Hutchinson, Aalin Izhar, Rebecca D. Jackson, Ruth F. Jarrett, Rudolph Kaaks, Eleanor Kane, Laurence N. Kolonel, Yinfei Kong, Peter Kraft, Anne Kricker, Annette Lake, Qing Lan, Charles Lawrence, Dalin Li, Mark Liebow, Brian K. Link, Corrado Magnani, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L. Milne, Thierry J. Molina, Alain Monnereau, Rebecca Montalvan, Kari E. North, Anne J. Novak, Kenan Onel, Mark P. Purdue, Kristin A. Rand, Elio Riboli, Jacques Riby, Eve Roman, Gilles Salles, Douglas W. Sborov, Richard K. Severson, Tait D. Shanafelt, Martyn T. Smith, Alexandra Smith, Kevin W. Song, Lei Song, Melissa C. Southey, John J. Spinelli, Anthony Staines, Deborah Stephens, Heather J. Sutherland, Kaitlyn Tkachuk, Carrie A. Thompson, Herve Tilly, Lesley F. Tinker, Ruth C. Travis, Jenny Turner, Celine M. Vachon, Claire M. Vajdic, Anke Van den Berg, David J. Van den Berg, Roel C. H. Vermeulen, Paolo Vineis, Sophia S. Wang, Elisabete Weiderpass, George J. Weiner, Stephanie Weinstein, Nicole Wong Doo, Yuanqing Ye, Meredith Yeager, Kai Yu, Anne Zeleniuch-Jacquotte, Yawei Zhang, Tongzhang Zheng, Elad Ziv, Joshua Sampson, Nilanjan Chatterjee, Kenneth Offit, Wendy Cozen, Xifeng Wu, James R. Cerhan, Stephen J. Chanock, Susan L. Slager, Nathaniel Rothman
Article
Oncology
Marie Balsat, Vincent Alcazer, Gabriel Etienne, Francoise Huguet, Marc Berger, Emilie Cayssials, Aude Charbonnier, Martine Escoffre-Barbe, Hyacinthe Johnson-Ansah, Laurence Legros, Lydia Roy, Alain Delmer, Jean-Christophe Ianotto, Corentin Orvain, Fabrice Larosa, Mathieu Meunier, Shanti Ame, Annalisa Andreoli, Pascale Cony-Makhoul, Stephane Morisset, Isabelle Tigaud, Delphine Rea, Franck Emmanuel Nicolini
Summary: This retrospective study observed the clinical data of newly diagnosed accelerated phase chronic myeloid leukemia (AP-CML) patients who received second-generation tyrosine kinase inhibitors (TKI2) as first-line treatment. The results showed that TKI2 could effectively improve the survival and treatment response of patients.
Article
Medicine, General & Internal
Carole Durot, Eric Durot, Sebastien Mule, David Morland, Francois Godard, Anne Quinquenel, Alain Delmer, Philippe Soyer, Christine Hoeffel
Summary: The purpose of this study was to determine whether texture features on pretreatment unenhanced CT images derived from 18F-FDG PET/CT can predict survival outcomes in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. The study found that skewness at a fine texture scale and kurtosis without filtration were independent predictors of progression-free survival and time to next treatment. The results suggest that pretreatment unenhanced CT texture analysis-derived skewness and kurtosis can be used as predictive biomarkers for survival outcomes in patients with high-tumor-burden follicular lymphoma.